Clinical trials: Non-Alcoholic Steato-Hepatitis (NASH)
Non-alcoholic Fatty Liver Disease
Prospective Cohort Assessing the Role of the Genotoxin Colibactin From Escherichia Coli B2 in the Genesis of NASH
In a population of patients with Non Alcoholic Fatty Liver Disease (NAFLD), the investigators will compare the composition of the gut microbiota from patients with simple steatosis with that with steatohepatitis.
- Trial name
- Coli-NASH (NCT02390232)
- Testing
- liver biopsy, collection of stools, blood sample
- Where
- France
- Volunteers
- 176 people
- Sponsor
- University Hospital, Toulouse
Non-Alcoholic Fatty Liver Disease
NAFLD Study: US vs Liver Biopsy
Evaluate the diagnostic accuracy of the new ultrasound software vs hepatic histology, the current reference standard for the diagnosis of NAFLD and NASH in 20 obese patients (BMI> 30) candidates for laparoscopic bariatric surgery…
- Trial name
- NAFLD (NCT04101162)
- Testing
- shear waves elastography; liver biopsy
- Where
- Italy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
Type 2 Diabetes Mellitus, Obesity
The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes
This research study is being performed to begin to determine the effectiveness of two dominant bariatric surgery procedures versus an intensive lifestyle intervention to induce weight loss in patients and promote improvements in…
- Trial name
- TRIABETES (NCT01047735)
- Testing
- Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- University of Pittsburgh
Non-alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steato-Hepatitis (NASH)
Metabolic Surgery for Steato-Hepatitis
Non-alcoholic fatty liver disease (NAFLD) is associated with obesity and type 2 diabetes mellitus (T2DM) and is characterised by excess liver fat on imaging or histology. NAFLD affects up to 25% of the Western population.
- Trial name
- MeSH (NCT04282005)
- Testing
- Metabolic/Bariatric surgery, Lifestyle and Diet
- Where
- United Kingdom
- Volunteers
- 28 people
- Sponsor
- King's College London
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Steato-Hepatitis (NASH)
How Abnormal Function of Fat Tissue in Type 1 Diabetes Contributes to Fat in the Liver
Steatotic liver disease associated with metabolic dysfunction (MASLD) is a disease caused by excess fat storage in the liver. Excessive fat delivery to the liver and MASLD typically occurs in people with abdominal obesity and…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Steato-Hepatitis (NASH), Type 1 Diabetes Mellitus
- Trial name
- AGL14 (NCT07133854)
- Testing
- Imaging PET/MRI, Stable isotope infusions, meal test
- Where
- Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Université de Sherbrooke
NASH With Fibrosis, Diabete Type 2
Non-invasive Tests for Non-alcoholic Steato-hepatitis
The main objective is to study and validate a new approach for NASH and liver fibrosis diagnosis and personalized follow-up based on monocyte biomarkers and plasma metabolites.
- Conditions
- NASH With Fibrosis, Diabete Type 2, Obesity
- Trial name
- TEIRESEAS (NCT07502755)
- Testing
- Administration of Deuterated water
- Where
- Italy
- Volunteers
- 828 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Non Alcoholic Steatohepatitis
Bariatric Surgery Versus Non-alcoholic Steato-hepatitis
Bariatric-metabolic surgery is effective in treating the cluster of conditions forming the metabolic syndrome, strictly associated with NAFLD and NASH.
- Trial name
- BRAVES (NCT03524365)
- Testing
- RYGB, SG, Intensive Lifestyle Modification
- Where
- 3 sites in Italy
- Volunteers
- 288 people
- Sponsor
- Catholic University of the Sacred Heart
Non-alcoholic Steato-hepatitis
: Identification of Non-alcoholic Steato-hepatitis Cases in a Sample of Type 2 Diabetes Patients, with a Disruption of the Liver Function Tests, At the Pointe-à-Pitre University Hospital
Non-alcoholic steatohepatitis (NASH) develops on insulin resistance, especially in patients with carbohydrate tolerance. NASH may progress to more extensive fibrosis, including cirrhosis, but also to HCC with or without cirrhosis…
- Trial name
- STEATOGWAD (NCT06738810)
- Testing
- Fibrotest-actitest/NASHtest
- Where
- Guadeloupe
- Volunteers
- 103 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
NASH (Non-alcoholic Steato-hepatitis)
Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH
This study is to evaluate the effects of Rosiglitazone, insulin sensitizer and alpha-lipoic acid, antioxidant on patients with pathologically proved NASH (non-alcoholic steato-hepatitis).
- Trial name
- NCT01406704
- Testing
- Rosiglitazone, alpha-lipoic acid, Rosiglitazone/alpha-lipoic acid
- Volunteers
- 26 people
- Sponsor
- Seoul St. Mary's Hospital
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Liver Fibrosis/NASH
Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.
Metabolic dysfunction-associated steatotic liver disease (MASLD) (aka non-alcoholic fatty liver disease), commonly occurring in individuals with obesity and type 2 diabetes can lead to liver inflammation/ fibrosis.
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Liver Fibrosis/NASH, Non-Alcoholic Steato-Hepatitis (NASH)
- Trial name
- AGL13 (NCT06843148)
- Testing
- Niacin (250mg)
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- Université de Sherbrooke
Non-Alcoholic Steato-Hepatitis, Liver Cirrhosis
Genetic Studies of Non-Alcoholic Fatty Liver Disease
Background: Non-alcoholic fatty liver disease is the most common form of liver disease in the United States. It includes many conditions.
- Conditions
- Non-Alcoholic Steato-Hepatitis, Liver Cirrhosis, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT01629095
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
NASH - Nonalcoholic Steatohepatitis
Safety and Tolerability of HepaStem in Patients With Cirrhotic and Pre-cirrhotic NASH Patients
Multicenter, open-label, safety and tolerability study of ascending doses of HepaStem in patients with cirrhotic and pre-cirrhotic non-alcoholic steato-hepatitis (NASH) to determine the safety and tolerability of ascending single…
- Trial name
- PANASH (NCT03963921)
- Testing
- HepaStem
- Where
- 13 sites in Belgium, Bulgaria and 2 more
- Volunteers
- 23 people
- Sponsor
- Cellaion SA
Liver Cirrhosis
Intragastric Balloon in Compensated NASH(Non Alcoholic Steato Hepatitis) Cirrhotics
The study will be conducted in department of Hepatology at ILBS, the patients will be recruited from the OPD or IPD . The obese cirrhotic patients with NASH will be observed for standard of care and also patients who undergo IGB…
- Trial name
- NCT03753438
- Testing
- Intragstric Ballooning
- Where
- India
- Volunteers
- 56 people
- Sponsor
- Institute of Liver and Biliary Sciences, India